Preliminary report of a clinical trial supporting the sequential use of an attenuated E39 peptide E39 to optimize the immunologic response to the FBP E39 GM-CSF vaccineReport as inadecuate




Preliminary report of a clinical trial supporting the sequential use of an attenuated E39 peptide E39 to optimize the immunologic response to the FBP E39 GM-CSF vaccine - Download this document for free, or read online. Document in PDF available to download.

Journal for ImmunoTherapy of Cancer

, 3:P156

First Online: 04 November 2015DOI: 10.1186-2051-1426-3-S2-P156

Cite this article as: Jackson, D., Qiao, N., Greene, J.M. et al. j. immunotherapy cancer 2015 3Suppl 2: P156. doi:10.1186-2051-1426-3-S2-P156 Download fulltext PDF



Author: Doreen Jackson - Na Qiao - Julia M Greene - Diane Hale - John Berry - Alfred Trappey - Timothy Vreeland - Guy Clifton - N

Source: https://link.springer.com/







Related documents